Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

Alnylam doesn't have a drug out how is it trading at $43 per share??? The market is strange , there is no rational thinking on the stock market. Also GALE has one trial in phase 3 and their pipeline is not that big.

RXII has anti scarring $4 billion market, plus can to to eye indications afterwards which the ophthomology pipeline totals $10 billion alone. so $4 billion anti scarring + $10 billion otphthomology puts it at $14 billion dollars valuation.